Biognosys and Bruker Form Partnership for Advanced Proteomics CRO Services for Global Biopharma and Biomarker Customers

- New strategic partnership aims to broaden access to Biognosys’ leading CRO services and Spectronaut® software tools for unbiased proteomics and epiproteomics
- Expected to benefit proteomics research, disease biomarker discovery, drug discovery and development, and clinical trials leveraging pharmacoproteomics
- With Bruker investments, Biognosys plans to open advanced US proteomics CRO facility for proteomics biomarker and drug discovery and development, and pharmacoproteomics clinical trial support

SCHLIEREN, Switzerland and BILLERICA, Massachusetts, Jan. 04, 2023 (GLOBE NEWSWIRE) – Biognosys AG and Bruker Corporation (Nasdaq: BRKR) today announced a strategic partnership, in which Bruker has made a majority-ownership investment in Biognosys. Financial details were not disclosed. J.P.Morgan acted as exclusive financial advisor to Biognosys. Several of Biognosys’ earlier investors have sold their shares to Bruker in a secondary transaction, and Bruker will make new primary investments in Biognosys.

Co-Founder and CEO Dr. Oliver Rinner and his leadership team will continue to manage Biognosys as a world-leading proteomics and proteogenomics CRO services and proteomics software company. Going forward, Biognosys' biomarker and biopharma customers will benefit from additional services and footprint in the US. Biognosys will access Bruker’s leading 4D proteomics timsTOF technology for deeper, unbiased high-precision proteomics that is not impaired by epitope cross-reactivity - all with higher throughput and excellent reproducibility.

Biognosys mass spectrometry-based proteomics solutions help CRO services and proteomics software customers in uncovering connections between genome, transcriptome, and phenotype to explore the static and dynamic nature of disease biology. In particular, the Biognosys TrueTarget™, TrueDiscovery™, and TrueSignature™ research service solutions provide deep, peptide-level proteome insights for drug discovery and development:

- TrueTarget™ uniquely addresses pressing challenges in drug discovery by identifying on- and off-target effects, and characterizing binding sites.
- TrueDiscovery™, powered by Spectronaut® proteomics software, offers unbiased, multi-dimensional insights into the expression, function, and structure of up to 4,200 proteins in plasma, up to 11,000 proteins in other biofluids, and up to 13,800 proteins in tissue or cell lines.
- TrueSignature™ high-precision, customizable, multiplex panels enable simultaneous absolute quantification of proteins for pharmacodynamic readouts and clinical biomarker monitoring, in support of pharmacoproteomics-enhanced clinical trials.
The Bruker-Biognosys collaboration is expected to create unique synergies between Biognosys’ versatile portfolio of proprietary proteomics services, software and kits, and Bruker’s pioneering timsTOF platform. As a result of the strategic partnership, Biognosys plans to open its first advanced proteomics CRO services laboratory in the United States.

Dr. Oliver Rinner, CEO and Co-Founder of Biognosys, commented: “We are pleased to partner with Bruker to leverage our unique synergies to enable customers to explore the depth of the proteome from early research to clinical development. We have worked closely with Bruker to support dia-PASEF® high-throughput, deeper proteomics methods within our Spectronaut® software. Biognosys remains committed to maintaining Spectronaut® as a high-performance vendor-agnostic proteomics software. We plan to establish our US CRO lab in Massachusetts using the timsTOF platform, so that our customers can benefit from multiple MS technologies.”

Dr. Rohan Thakur, President of the Bruker Life-Science Mass Spectrometry division, said: “We are delighted to partner with Biognosys to expand our CRO business in the US. We have many common biomarker and biopharma customers, and even more potential customers may prefer a proteomics CRO services expert like Biognosys for rapid, highest quality and flexible insertion of proteomics into their biomarker or biopharma discovery and development. With the rapid scientific acceptance of dia-PASEF workflows, our partnership offers a unique combination of proteomics applications and data-science expertise, which can benefit more biopharma and diagnostics companies in using unbiased proteomics for decision-making.”

Professor emeritus and proteomics pioneer, Dr. Ruedi Aebersold, added: “For over a decade, ETH spin-off Biognosys has translated novel proteomics methods pioneered in our research group into robust, high-performance workflows for large-scale basic and translational research. I am delighted that this new partnership between Biognosys and Bruker will further accelerate access to high performance proteomics. It will also provide opportunities to develop next-generation technology and methods to determine unexplored but functionally relevant dimensions of the proteome, such as the modulation of proteoform composition, and protein interaction networks as a function of cellular state.”

About Biognosys AG

At Biognosys, we believe that deep proteome insights hold the key to breakthrough discoveries that can dramatically improve human health. We enable life science researchers, biomarker and drug hunters to look at the proteome from every angle with our versatile portfolio of proprietary next-generation proteomics services, software, and kits, including the TrueDiscovery™, TrueTarget™, and TrueSignature™ platforms and flagship proteomics software Spectronaut®. These solutions provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Biognosys’ unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins across thousands of
samples with industry-leading precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for biomarker and biopharma R&D, development and translational research. For more information, visit www.biognosys.com.

Media Contacts
Yves Serroen  Oliver Rinner, PhD
Biognosys AG   Biognosys AG
Head of Marketing and Communications  Chief Executive Officer and Co-Founder
T: +41 (0) 79 571 09 21  T: +41 (0) 44 738 20 47
E: yves.serroen@biognosys.com    E: oliver.rinner@biognosys.com

About Bruker Corporation (Nasdaq: BRKR)

Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in life science molecular and cell biology research, in applied and pharma applications, in microscopy and nanoanalysis, as well as in industrial applications. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. Please visit www.bruker.com.

Media Contact
Petra Scheffer
Bruker Daltonics Marketing Communications
T: +49 (421) 2205-2843
E: petra.scheffer@bruker.com

Investor Relations Contact
Justin Ward
Sr. Director Investor Relations & Corp Development
T: +1 (978) 663–3660, ext. 1479
E: Investor.Relations@bruker.com